TR200000993T2 - Endotelin antagonistleri. - Google Patents

Endotelin antagonistleri.

Info

Publication number
TR200000993T2
TR200000993T2 TR2000/00993T TR200000993T TR200000993T2 TR 200000993 T2 TR200000993 T2 TR 200000993T2 TR 2000/00993 T TR2000/00993 T TR 2000/00993T TR 200000993 T TR200000993 T TR 200000993T TR 200000993 T2 TR200000993 T2 TR 200000993T2
Authority
TR
Turkey
Prior art keywords
endothelin antagonists
prepare
antagonizing
endothelium
processes
Prior art date
Application number
TR2000/00993T
Other languages
English (en)
Inventor
Winn Martin
A. Boyd Steven
W. Hutchins Charles
Jae Hwan-Soo
S. Tasker Andrew
W. Von Geldern Thomas
A. Kester Jeffrey
K. Sorensen Bryan
G. Szczepankiewicz Bruce
J. Henry Kenneth
Liu Gang
J. Wittenberger Steven
A. King Steven
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/905,913 external-priority patent/US6162927A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of TR200000993T2 publication Critical patent/TR200000993T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Bir formül (I) bilesigi veya farmasötik olarak kabul edilebilir bir tuzu açiklanmaktadir; ayrica bunlari hazirlamak için islemler ve bunlari hazirlamak için kullanilan aramaddelerin yani sira endotelini antagonize etmek için bir yöntem açiklanmaktadir.
TR2000/00993T 1997-08-04 1998-07-27 Endotelin antagonistleri. TR200000993T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/905,913 US6162927A (en) 1994-08-19 1997-08-04 Endothelin antagonists
US4895598A 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
TR200000993T2 true TR200000993T2 (tr) 2000-12-21

Family

ID=26726720

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2001/01233T TR200101233T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.
TR2001/01234T TR200101234T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.
TR2000/00993T TR200000993T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.
TR2005/01137T TR200501137T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2001/01233T TR200101233T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.
TR2001/01234T TR200101234T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2005/01137T TR200501137T2 (tr) 1997-08-04 1998-07-27 Endotelin antagonistleri.

Country Status (16)

Country Link
EP (1) EP1003740A2 (tr)
JP (1) JP2001512119A (tr)
CN (1) CN1301264A (tr)
AU (1) AU748469B2 (tr)
BG (1) BG104216A (tr)
BR (1) BR9815296A (tr)
CA (1) CA2297894A1 (tr)
HU (1) HUP0003484A3 (tr)
IL (1) IL134175A0 (tr)
NO (1) NO20000542L (tr)
NZ (1) NZ502395A (tr)
PL (1) PL342500A1 (tr)
SK (1) SK1452000A3 (tr)
TR (4) TR200101233T2 (tr)
TW (1) TW552260B (tr)
WO (1) WO1999006397A2 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337230A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
CA2442591A1 (en) * 2001-04-11 2002-10-31 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2007034406A1 (en) * 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN104262329A (zh) * 2014-10-22 2015-01-07 南京友杰医药科技有限公司 反式阿曲生坦的制备
WO2024022262A1 (zh) * 2022-07-25 2024-02-01 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
WO1996006095A1 (en) * 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
HUP9902316A3 (en) * 1996-02-13 2001-12-28 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
US5618949A (en) * 1996-07-12 1997-04-08 Abbott Laboratories Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Also Published As

Publication number Publication date
SK1452000A3 (en) 2001-05-10
CA2297894A1 (en) 1999-02-11
WO1999006397A2 (en) 1999-02-11
BR9815296A (pt) 2001-11-20
HUP0003484A3 (en) 2002-02-28
TR200101234T2 (tr) 2002-06-21
BG104216A (bg) 2000-12-29
NO20000542D0 (no) 2000-02-02
NZ502395A (en) 2002-08-28
TR200101233T2 (tr) 2002-06-21
NO20000542L (no) 2000-04-04
WO1999006397A3 (en) 1999-12-09
AU8592198A (en) 1999-02-22
IL134175A0 (en) 2001-04-30
JP2001512119A (ja) 2001-08-21
EP1003740A2 (en) 2000-05-31
CN1301264A (zh) 2001-06-27
PL342500A1 (en) 2001-06-04
AU748469B2 (en) 2002-06-06
TR200501137T2 (tr) 2005-12-21
HUP0003484A2 (hu) 2002-01-28
TW552260B (en) 2003-09-11

Similar Documents

Publication Publication Date Title
TR200000993T2 (tr) Endotelin antagonistleri.
DE69831868D1 (en) Antithrombosemittel
DE69830504D1 (de) Antithrombotische mitteln
DE69709938T2 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
EA200401533A1 (ru) Способ получения росувастатина
DE69931393D1 (de) Antithrombotische amide
NO20083684L (no) Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer
EA199900907A1 (ru) 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич
ATE219077T1 (de) Endothelin antagoniste
BG105457A (en) Method for the preparation of citalopram
IL148932A0 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
TR199900486T2 (tr) Aziniloksi ve fenoksi-diaril-karbonasit türevleri.
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
EA200000094A1 (ru) Способ получения замещенного пергидроизоиндола
EA200100618A1 (ru) Антагонист витронектинового рецептора
ES8700242A1 (es) Un procedimiento para preparar un derivado de dihidropirida-zinona
ES8602631A1 (es) Procedimiento de producir compuestos para tratar la hipertension
NO996244L (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
EA199700395A1 (ru) Способ получения ингибиторов протеазы вируса иммунодефицита человека
ES2103590T3 (es) Derivados del acido 3-(indol-3-il) propenoico utilizables como antagonistas nmda.
MX9701220A (es) Antagonistas de endotelina.
ES8603871A1 (es) Procedimiento para preparar 2- (fenetil) -5- (3,4-metilen- dioxi)-x-hidroxibencil) -pirrolidina
NO903488D0 (no) Ny forbindelse.
DE69909273D1 (de) Phosphat-vermittelte cyclisierung